Abstract: A novel set of reconfiguration tools combine the RTL (Register Transfer Language) construct detection of synthesis compilers with a more advanced implementation of expansion syntax. HDL (Hardware Description Language) coding constructs are automatically detected and recoded and/or modified, for both behavioral and structural HDL code. Configuration file(s) may be used to define the transformations, and transformation commands within the configuration file(s) may define where and how to apply RTL changes. The tool may automatically identify sections of code as the file is parsed (e.g. like a compiler). The transformations are written out in RTL, and the resulting reconfigured RTL file(s) may be processed by a synthesis tool, or may be simulated using a suitable simulator. This allows for automated detection and configurable modification of HDL-coding constructs. Design changes may therefore be verified earlier in the design process, since changes are embedded in RTL, instead of being embedded in the netlist.

Abstract: Methods are provided for treating cancers that have high glucose requirements and that express SGLT2 at levels higher than normal cells, such as metastatic cancers, for example, metastatic lung cancers, employing an SGLT2 inhibitor alone or in combination with a cytotoxic agent and to a composition containing a combination of an SGLT2 inhibitor and a cytotoxic agent.

Abstract: A novel set of reconfiguration tools combine the RTL (Register Transfer Language) construct detection of synthesis compilers with a more advanced implementation of expansion syntax. HDL (Hardware Description Language) coding constructs are automatically detected and recoded and/or modified, for both behavioral and structural HDL code. Configuration file(s) may be used to define the transformations, and transformation commands within the configuration file(s) may define where and how to apply RTL changes. The tool may automatically identify sections of code as the file is parsed (e.g. like a compiler). The transformations are written out in RTL, and the resulting reconfigured RTL file(s) may be processed by a synthesis tool, or may be simulated using a suitable simulator. This allows for automated detection and configurable modification of HDL-coding constructs. Design changes may therefore be verified earlier in the design process, since changes are embedded in RTL, instead of being embedded in the netlist.

Abstract: Methods are provided for treating obesity or causing weight loss in a mammalian subject or patient, wherein a therapeutically effective amount of an SGLT2 inhibitor alone or optionally in combination with another anti-obesity agent, is administered to a mammalian subject or patient. In addition, a pharmaceutical composition is provided which comprises an SGLT2 inhibitor, alone or in combination with another anti-obesity agent, and a pharmaceutically acceptable carrier thereof.

Abstract: Methods are provided for treating obesity or causing weight loss in a mammalian subject or patient, wherein a therapeutically effective amount of an SGLT2 inhibitor alone or optionally in combination with another anti-obesity agent, is administered to a mammalian subject or patient. In addition, a pharmaceutical composition is provided which comprises an SGLT2 inhibitor, alone or in combination with another anti-obesity agent, and a pharmaceutically acceptable carrier thereof.

Abstract: Methods are provided for treating cancers that have high glucose requirements and that express SGLT2 at levels higher than normal cells, such as metastatic cancers, for example, metastatic lung cancers, employing an SGLT2 inhibitor alone or in combination with a cytotoxic agent and to a composition containing a combination of an SGLT2 inhibitor and a cytotoxic agent.

Abstract: Methods are provided for treating obesity or causing weight loss in a mammalian subject or patient, wherein a therapeutically effective amount of an SGLT2 inhibitor alone or optionally in combination with another anti-obesity agent, is administered to a mammalian subject or patient. In addition, a pharmaceutical composition is provided which comprises an SGLT2 inhibitor, alone or in combination with another anti-obesity agent, and a pharmaceutically acceptable carrier thereof.